Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate

 
• By Joseph Haas

The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.

business documents accounting with calculator and magnifying glass. concept for financial
Gilead's HIV franchise is flourishing, while cancer cell therapy is sluggish

More from Earnings

More from Business